Promega has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase, the company announced today.

According to a release, the enzyme will enhance Promega’s capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied and pharmaceutical molecular applications.

“Watchmaker’s enzyme offers a combination of attributes that establish a new benchmark for reverse transcriptase performance,” Promega VP of Commercial Excellence Sara Mann said in a statement. “By incorporating it into our portfolio, we are giving customers a powerful tool for improved accuracy and enhanced sensitivity of RNA-based assays.”

The partnership expands the Promega nucleic acid analysis portfolio.